Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE F : revenue, balance sheet and financial ratios

PHARMACIE F is a French company founded 6 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75013), this company of category PME shows in 2022 a net income positive of 337 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE F (SIREN 881482699)
Indicator 2022
Revenue N/C
Net income 336 884 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2022, PHARMACIE F generates positive net income of 337 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

336 884 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 109%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

109.301%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

33.859%

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

70.2%

Solvency indicators evolution
PHARMACIE F

Sector positioning

Debt ratio
109.3 2022
2022
Q1: 24.51
Med: 74.73
Q3: 182.48
Average

In 2022, the debt ratio of PHARMACIE F (109.30) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
33.86% 2022
2022
Q1: 28.54%
Med: 47.06%
Q3: 66.62%
Average

In 2022, the financial autonomy of PHARMACIE F (33.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 258.20. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

258.2

Liquidity indicators evolution
PHARMACIE F

Sector positioning

Liquidity ratio
258.2 2022
2022
Q1: 145.16
Med: 199.46
Q3: 274.98
Good

In 2022, the liquidity ratio of PHARMACIE F (258.20) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Positioning of PHARMACIE F in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 215 transactions of similar company sales in 2022, the value of PHARMACIE F is estimated at 3 963 948 € (range 2 664 561€ - 5 945 186€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2022
215 transactions
2664k€ 3963k€ 5945k€
3 963 948 € Range: 2 664 561€ - 5 945 186€
NAF 5 année 2022

Valuation method used

Net Income Multiple
336 884 € × 11.8x = 3 963 949 €
Range: 2 664 561€ - 5 945 187€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 215 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE F with other companies in the same sector:

Frequently asked questions about PHARMACIE F

What is the revenue of PHARMACIE F ?

The revenue of PHARMACIE F is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMACIE F profitable?

Yes, PHARMACIE F generated a net profit of 337 k€ in 2022.

Where is the headquarters of PHARMACIE F ?

The headquarters of PHARMACIE F is located in PARIS (75013), in the department Paris.

Where to find the tax return of PHARMACIE F ?

The tax return of PHARMACIE F is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE F operate?

PHARMACIE F operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.